The objective of this study is to analyze the efficacy of a new regimen using Bedaquiline,
Pretomanid, and Linezolid for 26 weeks (6 months) for the treatment of FQ-resistant MDR-TB
through the clinical trial. The recently completed Zenix trial observed that lower doses
and/or shorter durations of linezolid than 1200mg for 6 months appear to have high efficacy
and improved safety. Therefore, the primary objective of this study is to analyze the
effectiveness and safety of the BPaL regimen including modified dosing of linezolid for the
patients with fluoroquinolone-resistant MDR-TB.
Phase:
Phase 4
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Chonnam National University Hospital Funded by Korea Disease Control and Prevent Agency International Tuberculosis Research Center Investigational drug(Pretomanid) supported by Viatris Pharmaceutical Masan National Tuberculosis Hospital Pusan National University Hospital Samsung Medical Center Seoul National University Hospital Severance Hospital